Cargando…

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shengnan, Liu, Qian, Han, Xinwei, Qin, Shuang, Zhao, Weiheng, Li, Anping, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704598/
https://www.ncbi.nlm.nih.gov/pubmed/29209558
http://dx.doi.org/10.1186/s40164-017-0091-4
_version_ 1783281934294581248
author Yu, Shengnan
Liu, Qian
Han, Xinwei
Qin, Shuang
Zhao, Weiheng
Li, Anping
Wu, Kongming
author_facet Yu, Shengnan
Liu, Qian
Han, Xinwei
Qin, Shuang
Zhao, Weiheng
Li, Anping
Wu, Kongming
author_sort Yu, Shengnan
collection PubMed
description HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer. The resistance to anti-HER2 antibody has resulted in disease progression. HER2-directed bispecific antibody may be a promising therapeutic approach for these patients. Ertumaxomab enhanced the interaction of immune effector cells and tumor cells. MM-111 simultaneously binds to HER2 and HER3 and blocks downstream signaling. Besides, HER2Bi-aATC is also an alternative therapeutic approach for HER2 positive cancers. In this review, we summarized the recent advancement of HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab and T-DM1) and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC), especially focus on clinical trial results.
format Online
Article
Text
id pubmed-5704598
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57045982017-12-05 Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment Yu, Shengnan Liu, Qian Han, Xinwei Qin, Shuang Zhao, Weiheng Li, Anping Wu, Kongming Exp Hematol Oncol Review HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer. The resistance to anti-HER2 antibody has resulted in disease progression. HER2-directed bispecific antibody may be a promising therapeutic approach for these patients. Ertumaxomab enhanced the interaction of immune effector cells and tumor cells. MM-111 simultaneously binds to HER2 and HER3 and blocks downstream signaling. Besides, HER2Bi-aATC is also an alternative therapeutic approach for HER2 positive cancers. In this review, we summarized the recent advancement of HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab and T-DM1) and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC), especially focus on clinical trial results. BioMed Central 2017-11-28 /pmc/articles/PMC5704598/ /pubmed/29209558 http://dx.doi.org/10.1186/s40164-017-0091-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Yu, Shengnan
Liu, Qian
Han, Xinwei
Qin, Shuang
Zhao, Weiheng
Li, Anping
Wu, Kongming
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
title Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
title_full Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
title_fullStr Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
title_full_unstemmed Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
title_short Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
title_sort development and clinical application of anti-her2 monoclonal and bispecific antibodies for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704598/
https://www.ncbi.nlm.nih.gov/pubmed/29209558
http://dx.doi.org/10.1186/s40164-017-0091-4
work_keys_str_mv AT yushengnan developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment
AT liuqian developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment
AT hanxinwei developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment
AT qinshuang developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment
AT zhaoweiheng developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment
AT lianping developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment
AT wukongming developmentandclinicalapplicationofantiher2monoclonalandbispecificantibodiesforcancertreatment